Loading…
Can-Fite BioPharma Ltd. is projected to rise to $3.21 by 2027, a +1% move from its current price of $3.17. CANF is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $3.06 | $3.17 | $3.28 | -0.01% |
| Aug 6 | $3.02 | $3.17 | $3.33 | -0.02% |
| Aug 7 | $2.98 | $3.17 | $3.36 | -0.03% |
| Aug 8 | $2.96 | $3.17 | $3.40 | -0.04% |
| Aug 9 | $2.93 | $3.17 | $3.42 | -0.05% |
| Aug 10 | $2.91 | $3.17 | $3.45 | -0.06% |
| Aug 11 | $2.89 | $3.17 | $3.47 | -0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.89 | $3.17 | $3.47 | -0.06% |
| Week 2 | $2.78 | $3.17 | $3.60 | -0.13% |
| Week 3 | $2.70 | $3.16 | $3.71 | -0.19% |
| Week 4 | $2.63 | $3.16 | $3.80 | -0.26% |
| Week 5 | $2.57 | $3.16 | $3.88 | -0.32% |
| Week 6 | $2.52 | $3.16 | $3.95 | -0.38% |
| Week 7 | $2.48 | $3.16 | $4.02 | -0.45% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company that develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel.
Its lead drug candidate Piclidenoson has completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; CF602, which is in pre-clinical trial for the treatment of erectile dysfunction.
In addition, it offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors and develops a commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd.
and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
CANF is a stock in the Healthcare sector, with the current price listed at $3.23 and a market cap of $6.92M. It ranks 5105 by market capitalization. The longer-term forecast shows upside potential, with the average price projected to rise to $4.65 by 2030 and to as high as $11.16 by 2050, while the maximums reach $7.39 in 2030 and $24.19 in 2050.
Projected ROI climbs from 0% in 2026 to 43.9% by 2030 and dramatically to 245.6% by 2050, with bullish sentiment prominent in the later years.
A major floor 48.6% below — a decisive break under it would weaken the trend.
The nearest floor, 13.2% below — buyers have tended to step in here.
The nearest ceiling, 46.1% above — a clean break opens room to run.
A major ceiling 70.0% above — clearing it would confirm fresh momentum.
Key CANF support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CANF market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.19 | Sell | $3.20 | Sell |
| MA 10 | $3.24 | Sell | $3.23 | Sell |
| MA 20 | $3.29 | Sell | $3.25 | Sell |
| MA 50 | $3.22 | Sell | $3.27 | Sell |
| MA 100 | $3.23 | Sell | $3.70 | Sell |
| MA 200 | $4.58 | Sell | $6.38 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.39 | Neutral |
| Stoch RSI (14) | 2.68 | Buy |
| CCI (20) | -103.00 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -3.96 | Sell |
| Bollinger %B (20,2) | 0.25 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.06 | Buy |
| Awesome (5,34) | -0.05 | Sell |
| Ultimate (7,14,28) | 37.88 | Neutral |
| Momentum (10) | -0.25 | Sell |
| Aroon Osc (25) | 12.00 | Buy |
| Hull MA (9) | 3.19 | Sell |
| ADX (14) | 7.42 | Neutral |
| ATR (14) | 0.11 | Info |
In the near term, the sentiment is BEARISH, with an RSI(14) of 50. The price is near the SMA50 of $3.25 and below the SMA200 of $4.83. Support is at $2.75 and resistance at $4.63. The 30-day range runs from $2.48 up to $4.20.
These near-term indicators frame a trading band that could constrain moves in the immediate horizon, while the data shows a potential for longer-term upside as reflected in the multi-year forecast.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.75 | $3.17 | $3.92 | 0% | Neutral | |
| $2.50 | $3.21 | $4.40 | +1% | Neutral | |
| $2.71 | $3.62 | $5.19 | +14% | Neutral | |
| $2.83 | $3.89 | $5.78 | +23% | Bullish | |
| $3.20 | $4.52 | $6.91 | +42% | Bullish | |
| $2.98 | $4.32 | $6.79 | +36% | Bullish | |
| $2.57 | $3.81 | $6.12 | +20% | Bullish | |
| $2.73 | $4.14 | $6.80 | +31% | Bullish | |
| $2.69 | $4.17 | $6.97 | +32% | Bullish | |
| $3.02 | $4.77 | $8.11 | +50% | Bullish | |
| $3.06 | $5.30 | $9.70 | +67% | Bullish | |
| $5.57 | $11.39 | $23.15 | +259% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.75 | $3.17 | $3.64 | +0.00% |
| September 2026 | $2.50 | $2.98 | $3.67 | -5.90% |
| October 2026 | $2.62 | $3.14 | $3.92 | +5.38% |
| November 2026 | $2.61 | $3.16 | $3.98 | +0.51% |
| December 2026 | $2.53 | $3.08 | $3.92 | -2.50% |
Click any year to see its month-by-month CANF forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Can-Fite BioPharma Ltd.'s 2026 outlook centres on $3.17, within a $2.75 to $3.92 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CANF could reach as high as $4.40, with a base case around $3.21 and support toward $2.50 — roughly +1% from $3.17. Price action looks broadly range-bound.
Expect CANF to range from $2.71 to $5.19 through 2028. The $3.62 average target implies a +14% move from current prices. That is up +13% on the projected 2027 average. A consolidation phase looks the most probable path here.
The CANF price prediction for 2029 points to an average of $3.89 (low $2.83, high $5.78) — a potential gain of +23% on today's $3.17. Momentum favours further upside here.
In 2030, CANF is projected to trade between $3.20 and $6.91, averaging $4.52 — a potential gain of +42% from today's $3.17. That is up +16% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Can-Fite BioPharma Ltd.'s 2031 outlook centres on $4.32, within a $2.98 to $6.79 range. That is -4% versus the projected 2030 average. That marks a +36% change versus current levels. Momentum favours further upside here.
By 2032, CANF could reach as high as $6.12, with a base case around $3.81 and support toward $2.57 — roughly +20% from $3.17. Buyers look set to stay in control over this stretch.
Expect CANF to range from $2.73 to $6.80 through 2033. The $4.14 average target implies a +31% move from current prices. That is up +9% on the projected 2032 average. Momentum favours further upside here.
The CANF price prediction for 2034 points to an average of $4.17 (low $2.69, high $6.97) — a potential gain of +32% on today's $3.17. Buyers look set to stay in control over this stretch.
In 2035, CANF is projected to trade between $3.02 and $8.11, averaging $4.77 — a potential gain of +50% from today's $3.17. That is up +14% on the projected 2034 average. Momentum favours further upside here.
Can-Fite BioPharma Ltd.'s 2040 outlook centres on $5.30, within a $3.06 to $9.70 range. That is up +11% on the projected 2035 average. That marks a +67% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CANF could reach as high as $23.15, with a base case around $11.39 and support toward $5.57 — roughly +259% from $3.17. Momentum favours further upside here.
Investing $1,000 in CANF today (≈ 315.457413 CANF) could be worth
$3,594.54
+$2,594.54 (+259%) by 2050 · US Dollar
Based on the average projected CANF price of $11.39 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CANFwould be worth at today's price.
$1,000 invested in CANF on Jul 31, 2025 (≈ 74.626868 CANF) would be worth
$236.57
-$763.43 (-76.3%) today · 0.24× · US Dollar
Based on a CANF entry price of $13.4 vs. today's $3.17.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.19 | $993.73 | -0.6% |
| 1 month ago | $4.63 | $684.67 | -31.5% |
| 3 months ago | $2.93 | $1,081.91 | +8.2% |
| 6 months ago | $4.13 | $767.55 | -23.2% |
| 1 year ago | $13.4 | $236.57 | -76.3% |
| All time (5.0y) ago | $424 | $7.48 | -99.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CANF forecast.
Our base-case forecast reaches $6.30 around 2050.
Implied market cap at $6.30: $13.5M
The multi-year forecast shows a progression from neutral in the early years to bullish in the later years, with specific year-by-year stakes. The 2026 forecast sits at a min of $2.75, an average of $3.23, and a max of $4.04, with an ROI of 0% and a neutral sentiment. In 2027, the min is $2.45, the avg is $3.21, the max is $4.51, with a return of -0.6% and neutral sentiment.
The path turns more favorable in 2028 (avg $3.52, max $5.21, ROI 9.1%, neutral) and 2029 (avg $3.90, max $6.00, ROI 20.9%, bullish).
By 2030 the average price is projected at $4.65 with a max of $7.39 and an ROI of 43.9% in a bullish setting, followed by 2031 at average $4.28, max $6.99 and ROI 32.4% (bullish). The forecast for 2032 shows average $3.71, max $6.23 and ROI 15% with neutral sentiment, and 2033 at average $4.14, max $7.10 and ROI 28.1% bullish. 2034 is projected at average $3.95, max $6.91 (ROI 22.2%, bullish), and 2035 at average $4.54, max $8.10 (ROI 40.4%, bullish).
Longer-range years point to continued upside, with 2040 averaging $4.90 and a max of $9.47 (ROI 51.6%, bullish), and 2050 averaging $11.16 with a max of $24.19 (ROI 245.6%, bullish). These figures imply meaningful upside potential over the horizon, albeit with the usual uncertainties and without guarantees. Drivers and risks include variability in clinical development outcomes, regulatory approvals, and market dynamics impacting pricing and adoption in healthcare.
Tap a question to reveal the answer.
The 2030 forecast shows min $3.17, avg $4.65, max $7.39 with ROI 43.9% and sentiment BULLISH.
Near term shows neutral footing (2026: avg $3.23, ROI 0%; 2027: avg $3.21, ROI -0.6%), with bullish momentum emerging by 2029 and extending to 2050. The 2030-2050 outlook includes substantial upside (e.g., 2050 max $24.19 and ROI 245.6%), but these are estimates and not guarantees.
Yes. The 2030 forecast max is $7.39, which implies a potential to exceed $5 within that horizon.
Current price is $3.23 and market cap is $6.92M.
The 30-day range is $2.48 to $4.20.
Can-Fite BioPharma Ltd. Community Discussion
0Share your Can-Fite BioPharma Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.